Pharmacokinetics Ppt and 100 free full text articles

Pharmacokinetics - Drug disposition
Dr. Wilcke
Drug disposition.ppt

Tobacco Overview
Nicotine.ppt

Factors that affect pharmacotherapy
Seki A. Balogun, MD, FACP
Pharmacotherapy_Workshop11.ppt

Analytical Toxicology Pharmacokinetics and Pharmacodynamics
Pharmacokinetics.ppt

Pharmacokinetics
Pharmacokinetics.ppt

Drug Metabolism and Pharmacokinetics Core
DCT_Program/Uys.ppt

Pharmacokinetics in its simplest form
Pharmacokinetics.ppt

Antidiabetic Medications
Hy N Dang
AntidiabeticMedications.ppt

Anti-protozoal drugs
Antiparasitics.ppt

Drug Interactions, OTC Drugs, and Drug Abuse
Drug Interactions, OTC Drugs, and Drug Abuse.ppt

Antibiotics for Gram Positive Meningitis
Bhakti Patel
abx_for_gram_positive_meningitis.ppt

The scientific study of psychoactive drugs and their effects
pharmoverviewHakan.ppt

Anti-viral drugs
Anti-viral drugs.ppt

The Life Cycle of a Drug
Pharmacology_Basics.ppt

Models - putting the whole thing together
Dr. Jeff Wilcke
Models - putting the whole thing together.ppt

The Role of Drug Metabolism Studies in Optimizing Drug Candidates
Kenneth Santone, PhD, Bristol-Myers Squibb
The Role of Drug Metabolism.ppt
100 free full text published articles

1. Pharmacokinetics and pharmacodynamics of medication in asphyxiated newborns during controlled hypothermia. The PharmaCool multicenter study.
2. 99mTc-Labeled, PEGylated (NαHis)Ac-β3hLys-βAla-βAla-Gln7-Trp8-Ala9-Val10-Gly11-His12-Cha13-Nle14-NH2 .
3. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response.
4. Distinct neurobehavioural effects of cannabidiol in transmembrane domain neuregulin 1 mutant mice.
5. Pharmacokinetics, metabolism and toxicity of carbon nanotubes for biomedical purposes.
6. Bacillus coagulans: Monograph.
7. Development and stability studies of novel liposomal vancomycin formulations.
8. Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults.
9. Involvement of ubiquitination in decrease of intestinal P-glycoprotein in streptozotocin-induced diabetic mouse model.
10. Liposomal amphotericin B: a unique pharmacokinetic profile. An unfinished story.
11. 18F-1,4,7-Triazacyclononane-1,4,7-triacetic acid-10-maleimidoethylacetamide-Affibody ZHER2:2395 .
12. 111In-1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid-anti-insulin-like growth factor 1 receptor Affibody ZIGF1R:4551 .
13. Neonatal pharmacology: extensive interindividual variability despite limited size.
14. Pediatric pharmacokinetics of vancomycin: a canadian perspective.
15. Bivalirudin use in an infant with persistent clotting on unfractionated heparin.
16. Dosage of antipseudomonal antibiotics in patients with acute kidney injury subjected to continuous renal replacement therapies.
17. Optimizing Druggability through Liposomal Formulations: New Approaches to an Old Concept.
18. Torsade de Pointes and Persistent QTc Prolongation after Intravenous Amiodarone.
19. Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates.
20. NO-NSAIDs. Part 3: Nitric Oxide-Releasing Prodrugs of Non-steroidal Anti-inflammatory Drugs.
21. Study of Factors Affecting Drug Extraction during Continuous Hemofiltration and Hemodiafiltration, and the Contribution of Extraction to Systemic Clearance.
22. 111In-Labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetracetic acid-Glu{PEG4-Glucyclo(Lys(PEG4)-Arg-Gly-Asp-d-Phe)-cyclo(Lys(PEG4)-Arg-Gly-Asp-d-Phe)}-{PEG4-Glucyclo(Lys(PEG4)-Arg-Gly-Asp-d-Phe)-cyclo(Lys(PEG4)-Arg-Gly-Asp-d-Phe)} (PEG4 = 15 amino-4,7,10,13-tetraoxapentadecanoic acid).
23. 111In-Labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetracetic acid-Glu{PEG4-Glucyclo(Lys(Gly-Gly-Gly)-Arg-Gly-Asp-d-Phe)-cyclo(Lys(Gly-Gly-Gly)-Arg-Gly-Asp-d-Phe)}-{PEG4-Glucyclo(Lys(Gly-Gly-Gly)-Arg-Gly-Asp-d-Phe)-cyclo(Lys(Gly-Gly-Gly)-Arg-Gly-Asp-d-Phe)} (PEG4 = 15 amino-4,7,10,13-tetraoxapentadecanoic acid).
24. 111In-Labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetracetic acid-Glu{PEG4-Glucyclo(Lys-Arg-Gly-Asp-d-Phe)-cyclo(Lys-Arg-Gly-Asp-d-Phe)}-{PEG4-Glucyclo(Lys-Arg-Gly-Asp-d-Phe)-cyclo(Lys-Arg-Gly-Asp-d-Phe)} (PEG4 = 15 amino-4,710,13-tetraoxapentadecanoic acid).
25. Pharmacokinetics of mycophenolic acid and its phenyl glucuronide metabolite in kidney transplant recipients with renal impairment.
26. Preparation of evodiamine solid dispersions and its pharmacokinetics.
27. A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia.
28. Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults.
29. Structure-Activity Relationship Modeling for Predicting Interactions with Pregnane X Receptor by Recursive Partitioning.
30. Role of P-glycoprotein in intestinal absorption of FB2, a promising Abl/Src dual tyrosine kinase inhibitor.
31. Effect of intermittent hypobaric hypoxia on efficacy & clearance of drugs.
32. A Systems Biology Approach in Therapeutic Response Study for Different Dosing Regimens-a Modeling Study of Drug Effects on Tumor Growth using Hybrid Systems.
33. 18F-Labeled N-succinimidyl-4-fluorobenzoate–conjugated rat anti-mouse vascular endothelial growth factor receptor 2 monoclonal antibody linked to microbubbles.
34. The impact of team-based learning on a foundational pharmacokinetics course.
35. Identification and Characterization of a Novel Class of c-Jun N-terminal Kinase Inhibitors.
36. Pharmacologic properties of polyethylene glycol-modified Bacillus thiaminolyticus thiaminase I enzyme.
37. Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial.
38. 18F-Labeled 5-(5-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)benzofuran-2-yl)-N,N-dimethylpyridin-2-amine.
39. Drug Class Review: Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder: Final Update 4 Report Internet.
40. What it takes to understand and cure a living system: computational systems biology and a systems biology-driven pharmacokinetics-pharmacodynamics platform.
41. Prognostic values of filamin-A status for topoisomerase II poison chemotherapy.
42. Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients.
43. Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease.
44. A Model-Based Approach to Predicting the Human Pharmacokinetics of a Monoclonal Antibody Exhibiting Target-Mediated Drug Disposition.
45. Interaction of clarithromycin with cyclosporine in cats: pharmacokinetic study and case report.
46. Single dose pharmacokinetics of terbinafine in cats.
47. Drug-drug interaction analysis of pyronaridine/artesunate and ritonavir in healthy volunteers.
48. Population pharmacokinetics applied to optimising cisplatin doses in cancer patients.
49. 18F-Labeled 4-(5-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)benzofuran-2-yl)-N,N-dimethylbenzenamine.
50. Pharmacokinetic Study of Di-Phenyl-Di-(2,4-Difluobenzohydroxamato)Tin(IV): Novel Metal-Based Complex with Promising Antitumor Potential.
51. Outcome of the HORIZONS-AMI trial: bivalirudin enhances long-term survival in patients with ST-elevation myocardial infarction undergoing angioplasty.
52. Co-medication with benzodiazepines.
53. Pharmacokinetics and Excretion Studies on CDRI-85/92, an Antiulcer Proton Pump Inhibitor.
54. Pathophysiological considerations of seizures, epilepsy, and status epilepticus in the elderly.
55. Antimicrobial activity of Terminalia arjuna Wight & Arn.: an ethnomedicinal plant against pathogens causing ear infection.
56. The science and practice of lithium therapy.
57. Raltegravir in HIV-1 infection: Safety and Efficacy in Treatment-naïve Patients.
58. Development of botanical principles for clinical use in cancer: where are we lacking?
59. HemaMax™, a recombinant human interleukin-12, is a potent mitigator of acute radiation injury in mice and non-human primates.
60. Effects of intestinal flora on the expression of cytochrome P450 3A in the liver.
61. Site-specific chemical modification of human serum albumin with polyethylene glycol prolongs half-life and improves intravascular retention in mice.
62. MODELING DISEASE PROGRESSION AND ROSIGLITAZONE INTERVENTION IN TYPE 2 DIABETIC GOTO-KAKIZAKI RATS.
63. Swim training reduces metformin levels in fructose-induced insulin resistant rats.
64. The Safety of EXPAREL ® (Bupivacaine Liposome Injectable Suspension) Administered by Peripheral Nerve Block in Rabbits and Dogs.
65. Immunological response as a source to variability in drug metabolism and transport.
66. Impact of the herbal medicine Sophora flavescens on the oral pharmacokinetics of indinavir in rats: the involvement of CYP3A and P-glycoprotein.
67. Self-microemulsifying drug-delivery system for improved oral bioavailability of probucol: preparation and evaluation.
68. Correlation between radioactivity and chemotherapeutics of the (111)In-VNB-liposome in pharmacokinetics and biodistribution in rats.
69. Effects of simvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, after oral and intravenous administration in rats: possible role of P-glycoprotein and CYP3A4 inhibition by simvastatin.
70. Comparison of the pharmacokinetics of paracetamol from two generic products in patients after total gastric resection.
71. Effect of neuroleptics on cytochrome P450 2C11 (CYP2C11) in rat liver.
72. Ezetimibe--a new approach in hypercholesterolemia management.
73. Optimized Assays for Human UDP-Glucuronosyltransferase (UGT) Activities: Altered Alamethicin Concentration and Utility to Screen for UGT Inhibitors.
74. Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings.
75. In silico Models of Alcohol Dependence and Treatment.
76. Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis.
77. Response: fospropofol: pharmacokinetics?
78. Fospropofol: pharmacokinetics?
79. Dose escalation pharmacokinetics and lipid lowering activity of a novel farnesoid X receptor modulator: 16-Dehydropregnenolone.
80. Pharmacokinetics of venlafaxine and its major metabolite o-desmethylvenlafaxine in freely moving mice using automated dosing/sampling system.
81. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients.
82. Selective pulmonary artery perfusion with melphalan is equal to isolated lung perfusion but superior to intravenous melphalan for the treatment of sarcoma lung metastases in a rodent model.
83. Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data.
84. A phase I study evaluating the pharmacokinetics, safety and tolerability of an antibody-based tissue factor antagonist in subjects with acute lung injury or acute respiratory distress syndrome.
85. Vitamin C: a concentration-function approach yields pharmacology and therapeutic discoveries.
86. Pulmonary Disposition of Tedizolid following Administration of Once-Daily Oral 200-Milligram Tedizolid Phosphate in Healthy Adult Volunteers.
87. dAcquisition setting optimization and quantitative imaging for 124I studies with the Inveon microPET-CT system.
88. Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours.
89. Lymphatic transport and catabolism of therapeutic proteins after subcutaneous administration to rats and dogs.
90. Regiospecific and stereospecific triangulation of the structures of metabolites formed by sequential metabolism at multiple prochiral centers.
91. Metabolism, pharmacokinetics, tissue distribution, and stability studies of the prodrug analog of an anti-hepatitis B virus dinucleoside phosphorothioate.
92. A Novel Vitamin K(1) 2,3-Epoxide Reductase (VKOR) Inhibitor, 3-Acetyl-5-Methyltetronic Acid, Reduces Experimental Glomerulonephritis.
93. Combination of probenecid-sulphadoxine-pyrimethamine for intermittent preventive treatment in pregnancy.
94. Evaluation of blood-brain barrier transport and CNS drug metabolism in diseased and control brain after intravenous L-DOPA in a unilateral rat model of Parkinson's disease.
95. Inhibitory Effect of Polyphenol-Rich Fraction from the Bark of Acacia mearnsii on Itching Associated with Allergic Dermatitis.
96. Preclinical Disposition of GDC-0973 and Prospective and Retrospective Analysis of Human Dose and Efficacy Predictions.
97. Gender- and age-related differences in dosage and serum concentration of psychotropic drugs.
98. Ginsenoside Re: Its chemistry, metabolism and pharmacokinetics.
99. First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development.
100. High-pressure intrapleural chemotherapy: feasibility in the pig model.